
ZBIO Stock Forecast & Price Target
ZBIO Analyst Ratings
Bulls say
Zenas BioPharma is in a strong financial position with a reported net loss of $111.50MM in 2Q26. Their promising pipeline, including the potential blockbuster obexelimab, and a significant cash balance of $674MM give them a competitive edge, with continued platform advancement and upcoming catalysts in 2026 supporting an OUTPERFORM rating and PT of $45.
Bears say
Zenas BioPharma is facing risks to its future sales estimates, as there is no guarantee that their lead program will prove to be efficacious or have a desired dosing interval. Additionally, the company may face regulatory delays that could impact market uptake and financing requirements. There are also questions surrounding how Zenas will differentiate its oral CNS-penetrant BTK inhibitor from other therapies in development for primary progressive MS and non-active secondary progressive MS. The company's recent acquisition of in-process research and development for 10,000 also raises questions about their financial stability and ability to fund future developments.
This aggregate rating is based on analysts' research of Zenas Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
ZBIO Analyst Forecast & Price Prediction
Start investing in ZBIO
Order type
Buy in
Order amount
Est. shares
0 shares